Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives $8.63 Average PT from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have been assigned a consensus recommendation of “Hold” from the nine ratings firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $8.63.

Separately, HC Wainwright restated a “neutral” rating and set a $4.00 price target on shares of Fulcrum Therapeutics in a research report on Wednesday, February 26th.

Fulcrum Therapeutics Stock Performance

FULC opened at $3.09 on Tuesday. The firm has a market cap of $166.80 million, a price-to-earnings ratio of -9.97 and a beta of 2.20. The firm’s 50-day simple moving average is $3.55 and its 200-day simple moving average is $3.80. Fulcrum Therapeutics has a twelve month low of $2.78 and a twelve month high of $10.13.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.03). As a group, sell-side analysts anticipate that Fulcrum Therapeutics will post -0.16 EPS for the current fiscal year.

Institutional Trading of Fulcrum Therapeutics

Several hedge funds have recently modified their holdings of the stock. Suvretta Capital Management LLC raised its position in Fulcrum Therapeutics by 182.3% in the 4th quarter. Suvretta Capital Management LLC now owns 3,338,466 shares of the company’s stock worth $15,691,000 after purchasing an additional 2,155,675 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Fulcrum Therapeutics by 50.0% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 3,000,000 shares of the company’s stock valued at $14,100,000 after buying an additional 1,000,000 shares during the period. State Street Corp raised its position in shares of Fulcrum Therapeutics by 61.4% during the third quarter. State Street Corp now owns 1,680,229 shares of the company’s stock worth $5,998,000 after acquiring an additional 638,955 shares during the last quarter. Woodline Partners LP lifted its stake in shares of Fulcrum Therapeutics by 110.3% during the fourth quarter. Woodline Partners LP now owns 1,410,520 shares of the company’s stock valued at $6,629,000 after acquiring an additional 739,713 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Fulcrum Therapeutics by 1.0% during the third quarter. Geode Capital Management LLC now owns 1,320,862 shares of the company’s stock valued at $4,716,000 after acquiring an additional 13,485 shares during the period. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.